Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ebola survivors under the microscope: what happens after recovery?

NCT ID NCT04409405

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study in the Democratic Republic of the Congo followed 787 people who survived Ebola and their close contacts. Researchers tracked their health over time, looking for lingering virus, immune responses, and other infections. The goal was to better understand the long-term consequences of Ebola and how to prevent further spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve how we monitor and care for Ebola survivors and help prevent future outbreaks by understanding how the virus lingers or spreads.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove that any intervention works, and results may not apply to other regions or outbreaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

787 people

The number who actually took part.

Started

Apr 2020

Finished

Oct 2021

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cured patients: study team will approach every declared-cured EBOV-infection patients discharged of a Ebola treatment center (Beni, Butembo, Mambassa or Mangina), older than 5 year old Contact participants: Cured participants will identify contact with who they were in contact when ill.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In cured population * Age ≥ 5 years * Adults and children after an acute episode declared cured of biologically confirmed Ebola virus disease (two negative PCRs are required at least 24 hours apart so that a patient without clinical symptoms can leave the Ebola treatment center), * Informed consent signed by at least one of the two parents or the legal guardian authorizing the child's participation in the study, * Volunteer participant who signed the informed consent for adults. In CONTACT population * Age ≥ 5 years, * Be a contact person of a cured patient (ie patient with a proven EVD, and with two negative PCRs at least 24 hours apart) included in the cohort of Ebola Winners. Based on WHO recommendations and the Centers for Disease Control and Prevention for the identification and traceability of contact subjects: a contact person is defined as a person who encountered the index case during his EVD in his residence, ie having the same place of life as him, * Have not been diagnosed with EVD, * Participation agreement: * For adult participants (≥ 18 years old, emancipated or married): informed consent intended for the adult participant signed, * For minors ≥ 5 years old: informed consent intended for the parent(s)/legal guardian signed by at least one of the two parents or the legal guardian and assent form intended for the minor participant completed. In cellular immunological sub-study: * Adult participants in the parent study ≥ 18 years old, * Accept to participate in this sub-study * Negative blood EBOV PCR Exclusion Criteria: * Absence of possible follow-up over 12 months from a logistical or geographical point of view (only for cured patients); * Non-residents in the DRC; * Impossibility of complying with the requirements and procedures of the study in the opinion of the investigator; * Inability to consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beni Hospital

    Beni, Democratic Republic of the Congo

  • Butembo Hospital

    Butembo, Democratic Republic of the Congo

  • Mambasa Hospital

    Mambasa, Democratic Republic of the Congo

  • Mangina Hospital

    Beni, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.